Live Breaking News & Updates on Drove Significant Revenue

Revenue Increased by 63.5% Y-o-Y to RMB7,206.4 Million Gross Profit Increased by 48.6% Y-o-Y to RMB3,413.2 Million Net Profit Grew by 39.2% Y-o-Y to RMB2,621.2. ....

Nordrhein Westfalen , United States , New Jersey , Evusheld Tixagevimab , Chris Chen , Us Bureau Of Industry , Shareholders Of The Company , Manufacturing Organization , Wuxi Biologics Cayman Inc , Group Global Dual , China Ministry Of Commerce , Contract Research , Drug Product Services Generate New Growth , Us Department Of Commerce Unverified List , Wuxi Biologics Co Ltd , Company For The Reporting Period , Us Department Of Commerce , Revenue Increased , Profit Increased , Profit Grew , Net Profit Rose , Model Led Sustainable Long Term , Drove Significant Revenue , Integrated Projects , Commercial Manufacturing Revenue Increased , Strong Growth Driver ,